~12 spots leftby Apr 2026

BacterioPHAGE for Gastrointestinal Health 2 Study

(PHAGE2 Trial)

Recruiting in Palo Alto (17 mi)
Overseen byTiffany L Weir, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Colorado State University

Trial Summary

What is the purpose of this trial?

The BacterioPHAGE for Gastrointestinal Health-2 study is designed to determine if a commercial bacteriophage product can increase the survival and efficacy of probiotic bacteria that will be concurrently administered. Bacteriophages may act as prebiotics, which are traditionally defined as indigestible dietary components that selectively enhance specific bacterial species in the intestines to confer a health benefit. In this study, the "prebiotic" is a unique combination of bacteriophages, or viruses that infect bacteria. These phages are generally regarded as safe for human consumption and are presumed to function by infecting pro-inflammatory E. coli strains in the gut. The removal of these strains alters the gut environment to allow growth of more favorable bacteria, and the lysis products of these E. coli may be assimilated by beneficial species to enhance their populations.The phage product, PreforPro, has shown to be effective in culture-based and animal studies, but its efficacy in increasing specific probiotic species has not been demonstrated in humans. The investigators have previously shown that PreforPro is both safe and tolerable in a human population and does not broadly disrupt the gut microbiota as would be seen with antibiotic treatment.

Eligibility Criteria

Inclusion Criteria

18-65 years old
BMI 20 to 34.9
healthy

Treatment Details

Interventions

  • Bifidobacterium animals subsp. lactis BL04 (Probiotic)
  • PreforPro (Virus Therapy)
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Bifidobacterium animals subsp. lactis BL04+PreforProExperimental Treatment1 Intervention
15 mg capsule containing 1x 10\^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10\^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
Group II: Bifidobacterium animals subsp. lactis BL04Active Control1 Intervention
15 mg capsule containing 1x 10\^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
Group III: PlaceboPlacebo Group1 Intervention
15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Colorado State UniversityFort Collins, CO
Loading ...

Who Is Running the Clinical Trial?

Colorado State UniversityLead Sponsor

References